MDV3100 Phase III clinical trial data showed positive survival results in men with advanced prostate cancer, increasing median survival by 4.8 months. Data results led the Independent Data Monitoring Committee (IDMC) to recommend stopping MDV3100 clinical trials and provide patients with MDV3100 who previously received the placebo. MDV3100 is the first androgen receptor signaling inhibitor to successfully meet clinical criteria and improve overall survival compared to placebo.
 
The Prostate Cancer Foundation provided a $500,000 research award to Owen Witte, MD, Charles Sawyers, MD, Michael Jung, PhD, with the University of California Los Angeles in 2002. Dr. Sawyers is currently at Memorial Sloan-Kettering Cancer Center.
 
The work that was performed with PCF funding resulted in not only establishing the androgen receptor as a drug target in castration-resistant prostate cancer but also led to the synthesis of what is now known as MDV3100. Furthermore, PCF support of the Prostate Cancer Clinical Trial Consortium, under the leadership of Howard Scher, MD, of Memorial Sloan-Kettering Cancer Center, propelled the successful development of this novel therapy.
 
“The clinical advancement of MDV3100 is one of the most important events in the history of prostate cancer research and the Prostate Cancer Foundation,” said Howard Soule, PhD, chief science officer and executive vice president of PCF. “For men whose disease has progressed since receiving hormone therapy and docetaxel chemotherapy, MDV3100 should provide a new therapy to extend survival.”
 
Medivation Inc. (a company that acquires early-development drugs, including MDV3100) plans to meet with the U.S. Food and Drug Administration early 2012 to discuss when they might seek approval for the drug.

Read the Full Press Release Here

Back to Research and Therapeutics